 |
|
C-Reactive Protein and Risk of Cardiovascular Disease in Men and Women From the Framingham Heart Study
Peter W. F. Wilson, MD;
Byung-Ho Nam, PhD;
Michael Pencina, PhD;
Ralph B. D’Agostino Sr, PhD;
Emelia J. Benjamin, MD, MS;
Christopher J. O’Donnell, MD, MPH
Arch Intern Med. 2005;165:2473-2478.
Background Determination of C-reactive protein (CRP) level has been suggested to improve cardiovascular disease (CVD) risk assessment. This study examines the utility of CRP levels to assess CVD risk in a community setting.
Methods We performed a prospective observational cohort study on a community population sample. A total of 1949 men and 2497 women without CVD from the Framingham Heart Study underwent CVD risk factor assessment. Initial CVD events during 8 years of follow-up were recorded.
Results There were 283 major CVD and 160 major coronary heart disease incident events. Age-, sex-, and multivariable-adjusted analyses generally used CRP level categories of less than 1, 1 to 3, and greater than 3 mg/L. In age- and sex-adjusted models, the traditional risk factors and elevated CRP levels indicated increased risk. The age- and sex-adjusted relative risk (RR) and 95% confidence interval (CI) of CRP level greater than 3 mg/L for major CVD was elevated (RR, 1.60; 95% CI, 1.19-2.14), with evidence of attenuation (RR, 1.22; 95% CI, 0.90-1.66) in multivariable models. The C statistic, a measure of the discriminatory capability of the prediction models, was 0.74 for prediction of major CVD with age and CRP level. In multivariable models that included traditional risk factors, the C statistic was 0.78, a value that was unchanged with the addition of CRP to the multivariable model. Similar relations were noted for major coronary heart disease events.
Conclusion Elevated CRP level provided no further prognostic information beyond traditional office risk factor assessment to predict future major CVD and major coronary heart disease in this population sample.
Author Affiliations: General Clinical Research Center, Medical University of South Carolina, Charleston (Dr Wilson); Department of Mathematics (Drs Nam, Pencina, and D’Agostino) and Department of Cardiology, School of Medicine (Dr Benjamin), Boston University, Boston, Mass; and the National Heart, Lung, and Blood Institute’s Framingham Heart Study, National Heart, Lung, and Blood Institute, Framingham, Mass (Dr O’Donnell).
RELATED LETTERS
The Role of Inflammation for Heart Disease Risk Cannot Be Determined by Correlations Between C-Reactive Protein and Risk Factors—Reply
Michael Miller and Stephen Havas
Arch Intern Med. 2006;166(9):1040-1041.
EXTRACT
| FULL TEXT
C-Reactive Protein and Cardiovascular Risk in the Framingham Study
Paul Ridker, Nader Rifai, Wolfgang Koenig, and Roger S. Blumenthal
Arch Intern Med. 2006;166(12):1327-1328.
EXTRACT
| FULL TEXT
C-Reactive Protein and Cardiovascular Risk in the Framingham Study—Reply
Peter W. F. Wilson, Michael Pencina, Ralph B. D’Agostino, Sr, and Christopher J. O’Donnell
Arch Intern Med. 2006;166(12):1328.
EXTRACT
| FULL TEXT
RELATED ARTICLES
When Is a New Prediction Marker Useful?: A Consideration of Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Stroke Risk
Philip Greenland and Patrick G. O’Malley
Arch Intern Med. 2005;165(21):2454-2456.
EXTRACT
| FULL TEXT
Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study
Christie M. Ballantyne, Ron C. Hoogeveen, Heejung Bang, Josef Coresh, Aaron R. Folsom, Lloyd E. Chambless, Merle Myerson, Kenneth K. Wu, A. Richey Sharrett, and Eric Boerwinkle
Arch Intern Med. 2005;165(21):2479-2484.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Importance of a Patient's Personal Health History on Assessments of Future Risk of Coronary Heart Disease
Mainous et al.
J Am Board Fam Med 2008;21:408-413.
ABSTRACT
| FULL TEXT
Estimating the capacity for improvement in risk prediction with a marker
Gu and Pepe
Biostatistics 2008;0:kxn025v1-kxn025.
ABSTRACT
| FULL TEXT
C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD
de Torres et al.
Chest 2008;133:1336-1343.
ABSTRACT
| FULL TEXT
Cardiovascular Outcomes in the Outpatient Kidney Transplant Clinic: The Framingham Risk Score Revisited
Kiberd and Panek
CJASN 2008;3:822-828.
ABSTRACT
| FULL TEXT
The LDL to HDL Cholesterol Ratio as a Valuable Tool to Evaluate Coronary Heart Disease Risk
Fernandez and Webb
J. Am. Coll. Nutr. 2008;27:1-5.
ABSTRACT
| FULL TEXT
Adherence to the Mediterranean Diet Is Inversely Associated With Circulating Interleukin-6 Among Middle-Aged Men: A Twin Study
Dai et al.
Circulation 2008;117:169-175.
ABSTRACT
| FULL TEXT
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus
Ridker
J Am Coll Cardiol 2007;49:2129-2138.
ABSTRACT
| FULL TEXT
State of the Art Reviews: The Anti-Inflammatory Actions of Exercise Training
Flynn et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:220-235.
ABSTRACT
Relative Value of Inflammatory, Hemostatic, and Rheological Factors for Incident Myocardial Infarction and Stroke: The Edinburgh Artery Study
Tzoulaki et al.
Circulation 2007;115:2119-2127.
ABSTRACT
| FULL TEXT
C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
Sattar et al.
Circulation 2007;115:981-989.
ABSTRACT
| FULL TEXT
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
Wang et al.
NEJM 2006;355:2631-2639.
ABSTRACT
| FULL TEXT
Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study
Sinning et al.
Eur Heart J 2006;27:2962-2968.
ABSTRACT
| FULL TEXT
The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets?
Blankenberg and Yusuf
Circulation 2006;114:1557-1560.
FULL TEXT
High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke: The Rotterdam Study
Bos et al.
Circulation 2006;114:1591-1598.
ABSTRACT
| FULL TEXT
Peripheral Blood CD34+KDR+ Endothelial Progenitor Cells Are Determinants of Subclinical Atherosclerosis in a Middle-Aged General Population
Fadini et al.
Stroke 2006;37:2277-2282.
ABSTRACT
| FULL TEXT
Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study
Blankenberg et al.
Circulation 2006;114:201-208.
ABSTRACT
| FULL TEXT
Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease
Lloyd-Jones et al.
ANN INTERN MED 2006;145:35-42.
ABSTRACT
| FULL TEXT
C-Reactive Protein and Cardiovascular Risk in the Framingham Study--Reply
Wilson et al.
Arch Intern Med 2006;166:1328-1328.
FULL TEXT
C-reactive protein and cardiovascular risk in the framingham study.
Ridker et al.
Arch Intern Med 2006;166:1327-1328.
FULL TEXT
Proinflammatory changes in human umbilical cord vein endothelial cells can be induced neither by native nor by modified CRP
Oroszlan et al.
Int Immunol 2006;18:871-878.
ABSTRACT
| FULL TEXT
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan
Circulation 2006;113:2335-2362.
FULL TEXT
The Role of Inflammation for Heart Disease Risk Cannot Be Determined by Correlations Between C-Reactive Protein and Risk Factors--Reply
Miller and Havas
Arch Intern Med 2006;166:1040-1041.
FULL TEXT
High sensitivity C-reactive protein in cardiovascular disease and type 2 diabetes: evidence for a clinical role?
Sattar
British Journal of Diabetes & Vascular Disease 2006;6:5-8.
When Is a New Prediction Marker Useful?: A Consideration of Lipoprotein-Associated Phospholipase A2 and C-Reactive Protein for Stroke Risk
Greenland and O'Malley
Arch Intern Med 2005;165:2454-2456.
FULL TEXT
|
